TANDEM DIABETES CARE INC
Form 3
November 13, 2013

(Print or Type Responses)

1. Name and Address of Reporting Person. ${ }^{\text {. }}$
Â CAHILL EDWARD L
(Last) (First) (Middle)

C/O HLM VENTURE
PARTNERS,,Â 222 BERKELEY
STREET
(Street)

BOSTON,Â MAÂ 02116
(City) (State) (Zip)
1.Title of Security
(Instr. 4)

| 2. Date of Event Requiring | 3. Issuer Name and Ticker or Trading Symbol |
| :--- | :--- | :--- |
| Statement <br> (Month/Day/Year) | TANDEM DIABETES CARE INC [TNDM] |
| $11 / 13 / 2013$ 4. Relationship of Reporting 5. If Amendment, Date Original <br>  Person(s) to Issuer Filed(Month/Day/Year) |  |

(Check all applicable)

| —X_Director | _X_10\% Owner |  |
| :--- | :--- | :--- |
| (give title below) | (specify below) | 6. Individual or Joint/Group |
|  | Filing(Check Applicable Line) |  | _X_Form filed by One Reporting Person __ Form filed by More than One Reporting Person

## Table I - Non-Derivative Securities Beneficially Owned

| 2. Amount of Securities 3. | 4. Nature of Indirect Beneficial |  |
| :--- | :--- | :--- |
| Beneficially Owned | Ownership | Ownership |
| (Instr. 4) | Form: | (Instr. 5) |
|  | Direct (D) |  |
|  | or Indirect |  |
|  | (I) |  |
|  | (Instr. 5) |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) |  | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |  | 4. Conversion or Exercise Price of Derivative | 5. <br> Ownership <br> Form of Derivative Security: | 6. Nature of Indirect <br> Beneficial <br> Ownership <br> (Instr. 5) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  | Title |  |  |  |  |
|  | Exercisable | Date | Title |  |  | Direct (D) |  |

## Edgar Filing: TANDEM DIABETES CARE INC - Form 3

|  |  |  |  | Shares |  | or Indirect <br> (I) <br> (Instr. 5) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Series C Preferred Stock | A ${ }^{(1)}$ | Â ${ }^{(2)}$ | Common <br> Stock | 223,684 | \$ 0 | I | Directly owned by HLM Venture Partners II, L.P. (3) |
| Series D Preferred Stock | A ${ }^{(1)}$ | Â ${ }^{(2)}$ | Common <br> Stock | 1,230,374 | \$ 0 | I | Directly owned by HLM Venture Partners II, L.P. (3) |
| Preferred Stock Warrant | A ${ }^{(4)}$ | 08/17/2021 | Series D <br> Preferred <br> Stock ${ }^{(5)}$ | 87,662 ${ }^{(5)}$ | \$ 4.4 (5) | I | Directly owned by HLM Venture Partners II, L.P. (3) |
| Preferred Stock Warrant | A ${ }^{(4)}$ | 05/25/2022 | Series D <br> Preferred <br> Stock ${ }^{(6)}$ | 21,915 (6) | \$ 4.4 (6) | I | Directly owned by HLM Venture Partners II, L.P. (3) |
| Preferred Stock Warrant | A ${ }^{(4)}$ | 07/17/2022 | Series D <br> Preferred <br> Stock ${ }^{(7)}$ | 33,014 | \$ 4.4 (7) | I | Directly owned by HLM Venture Partners II, L.P. (3) |

## Reporting Owners

Reporting Owner Name / Address
Relationships
Director 10\% Owner Officer Other

CAHILL EDWARD L
C/O HLM VENTURE PARTNERS, 222 BERKELEY STREET
BOSTON,Â MAÂ 02116

## Signatures

/s/ David B. Berger, Attorney-in-Fact for Edward L. Cahill

11/13/2013
${ }^{* *}$ Signature of Reporting Person
Date

## Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. $78 \mathrm{ff}(\mathrm{a})$.
(1) The securities are immediately convertible.
(2) The expiration date is not relevant to the conversion of these securities.
(3) The Reporting Person is a managing member of HLM Venture Associates II, L.L.C. ("Associates"), the general partner of HLM Venture Partners II, L.P. ("Partners"). As a managing member of Associates, the Reporting Person shares voting and investment power over the securities held by Partners and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims


## Edgar Filing: TANDEM DIABETES CARE INC - Form 3

beneficial ownership of such securities held by Partners, except to the extent of his proportionate pecuniary interest therein.
(4) The warrants are immediately exercisable.
(5) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 52,316 shares of the Issuer's common stock at an exercise price of $\$ 4.40$ per share.
(6) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 13,078 shares of the Issuer's common stock at an exercise price of $\$ 4.40$ per share.
(7) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 19,702 shares of the Issuer's common stock at an exercise price of $\$ 4.40$ per share.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

